マウス膀胱腫瘍(MBT-2)に対するTNFと癌化学療法剤との併用効果の検討

概要

論文の詳細を見る
マウス膀胱腫瘍(MBT-2)を用いてin vivoでTNFと各種癌化学療法剤(5-FU, CPM, CDDP, ADM)との併用効果を検討した.MBT-2にC3H/HeNマウスに移植し,移植後10日目よりTNF 3,000単位を10日間連続で腹腔内投与し各種癌化学療法剤は移植後10日目に1回だけ腹腔内投与を行った.腫瘍移植後20日目に効果を検討した.5-FU, CPM, ADMはTNFと併用することにより抗腫瘍効果が増強されたがCDDPでは増強効果を認めなかったThe antitumor activity of combination therapy of recombinant human tumor necrosis factor alpha (rHu-TNF alpha) and chemotherapeutic agents against murine bladder tumor (MBT-2) was studied. Tumors were intradermally transplanted into the hind leg of C3H-HeN mice and allowed to grow until they reached a diameter of 8 to 10 mm 10 days after transplantation. TNF (3,000 units) was given intraperitoneally from day 10 to day 19, and the chemotherapeutic agents, 5-FU (60 mg/kg), CPM (100 mg/kg), CDDP (10 mg/kg) and ADM (5 mg/kg), were applied once intraperitoneally on day 10. The antitumor effects were evaluated based on tumor volume on day 20. 5-FU, CPM and ADM enhanced the antitumor effect when combined with TNF, but CDDP did not. These findings suggest that combination therapy of TNF and certain antitumor chemotherapeutic agents is effective cancer treatment.